A lung cancer diagnosis hits hard. Whether it came after weeks of investigation or as a shock after a routine scan, you are almost certainly facing a cascade of urgent questions — about treatment, prognosis, and money. This guide addresses the medical aid questions specifically, so you can spend your energy on your care rather than fighting your scheme.
Take a Breath — You Have Cover
Lung cancer is a Prescribed Minimum Benefit (PMB) condition. Your medical aid cannot refuse to cover your diagnosis and treatment. Whatever plan you are on, whatever waiting period may apply to other conditions, the PMB regulations mean your scheme must fund your lung cancer treatment. The questions from here are not whether you're covered, but how much is covered, and for what.
Step 1: Understand Your PMB Status
Lung cancer is covered under the PMB framework as a Level 1 oncological condition. In practical terms, this means:
- Diagnosis and staging (CT, PET/CT, biopsy, bronchoscopy) must be funded.
- Surgery (lobectomy, pneumonectomy, wedge resection) must be funded at your designated service provider (DSP).
- Radiation therapy must be funded.
- Standard chemotherapy (platinum-based doublets) must be funded.
What the PMB does not automatically cover: - Targeted therapy (osimertinib for EGFR mutations, alectinib for ALK rearrangements, etc.) — these require exceptional-needs authorisation. - Immunotherapy (pembrolizumab, nivolumab, atezolizumab) — also exceptional-needs, regardless of your PD-L1 status. - Molecular testing (EGFR, ALK, ROS1, KRAS, PD-L1) — critical for treatment planning, but funding is inconsistent across schemes. If not covered, pay out of pocket — do not skip these tests.
Step 2: Make the First Call — Oncology Case Management
Before your next oncologist appointment, call your scheme's member services and ask specifically to be connected to oncology case management — not the general call centre. Tell them:
- You have been diagnosed with lung cancer.
- You need to register your PMB oncology benefit.
- You need a dedicated case manager assigned to your treatment.
This one call significantly reduces the risk of claims being incorrectly processed, pre-authorisations being missed, and exceptional-needs applications going astray. A case manager who is active from diagnosis is worth their weight in gold.
Step 3: Find Your Oncology Sub-Limit
Every plan has an annual rand cap on oncology treatment — your oncology sub-limit. This is separate from your overall benefit threshold. Find it now on your scheme's app, benefit guide, or by asking your case manager directly.
Common ranges in the South African market: - Entry-level hospital plans: R100,000–R200,000 (usually inadequate for systemic treatment) - Mid-tier plans: R250,000–R400,000 - Comprehensive plans: R500,000–R800,000 - Executive / unlimited oncology: No rand cap
If your oncologist projects treatment costs above your sub-limit, you need to act before starting treatment: - You can move to a higher plan option within the same scheme without a new waiting period — confirm this with your scheme. - The sub-limit question is especially urgent if you have a targetable mutation (EGFR, ALK) or high PD-L1 expression, as those treatment regimens cost R500,000–R800,000+ per year.
Step 4: Start the Exceptional-Needs Application Early
If your molecular testing shows a targetable mutation (EGFR, ALK, ROS1, KRAS G12C) or high PD-L1 expression, your oncologist will want to prescribe targeted therapy or immunotherapy. The scheme will require an exceptional-needs authorisation before they fund these medicines.
Do this immediately: 1. Ask your oncologist to submit the exceptional-needs application at the same time as your initial PMB registration — not after your first round of chemotherapy. 2. The application must include: molecular test results, your pathology report, staging information, and a motivation explaining why the targeted therapy is the appropriate treatment for your specific tumour profile. 3. Turnaround time is typically 5–15 business days. The application can be urgent-escalated if treatment is time-sensitive. 4. If declined: request written reasons, have your oncologist enhance the motivation, and submit a formal appeal.
Step 5: Check Your Medication Cover
Lung cancer is unusual in that some of the most effective treatments are oral daily tablets (osimertinib, alectinib, erlotinib, gefitinib), not infusions. If these are approved under exceptional needs, confirm whether they will be funded:
- As a chronic medication benefit (for ongoing oral targeted therapy)
- Or as an oncology benefit (paid from your oncology sub-limit)
This classification affects which rand pool is depleted. Ask your case manager explicitly.
Step 6: Assess Whether You Should Switch Plans
If your current plan's oncology sub-limit is insufficient for your projected treatment costs, consider moving to a higher option within your scheme before treatment starts. The plan change takes effect from the new plan year (1 January) if you apply during the October–November open-enrolment window, or with your scheme's approval outside this window for life events including new diagnoses.
Do not move to an entirely new scheme after a lung cancer diagnosis without specific financial advice. New-scheme waiting periods apply to pre-existing conditions. Moving away from a scheme while in treatment is a high-risk step.
Step 7: Emergency Resources
CANSA (Cancer Association of South Africa): 0800 22 6622 (toll-free, weekdays 08:00–16:30) Provides patient navigation, emotional support, counselling, and practical assistance for cancer patients.
Lung Cancer Foundation of South Africa: lungcancerfoundation.org.za Council for Medical Schemes (CMS) complaints: 0861 123 267 | www.medicalschemes.co.za If your scheme declines a PMB service, the CMS adjudication process is free.
What AURA Does Differently
Standard plan comparison tools show you premiums. AURA shows you what your specific condition will actually cost on each plan — oncology sub-limit, exceptional-needs track record, DSP network access. Free. 10 minutes.
Get help understanding your cover options →